Sangamo BioSciences to Present Preclinical Data and Scientific Advances At the 2003 Annual Meeting of the American Society of Gene Therapy

WASHINGTON, June 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Sangamo scientists and their corporate and academic collaborators have been selected to make 11 presentations at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT) to be held in Washington, DC, June 4-8, 2003. The presentations focus on the company's advances in ZFP Therapeutics(TM), zinc finger DNA-binding proteins (ZFPs) that are being developed for use in patients to treat and cure human disease.

"This year's ASGT Meeting is an important one for Sangamo. We will update the scientific community and our investors on the results of preclinical studies from our lead therapeutic program; ZFP transcription factors (ZFP TFs) that upregulate the VEGF A gene for the treatment of peripheral arterial disease, and present preliminary data from our newest initiative, ZFP-Mediated Gene Correction," said Edward Lanphier, Sangamo's president and chief executive officer. "Additionally, we will describe work that demonstrates the singular specificity of ZFP TFs for regulation of endogenous genes. The data being presented here by Sangamo scientists and our collaborators reflect the growing maturity of our ZFP Therapeutic development program."

Other presentations at the meeting will describe studies focused on the delivery of ZFP Therapeutics and advances in adenovirus production. In addition, Dr. Casey Case, Sangamo's vice president, research has been invited to co-chair a scientific session on Thursday, June 5, 2003 entitled "Gene Regulation: New Technology."

Sangamo Abstracts Being Presented

These abstracts are available on the ASGT website www.asgt.org. More detailed information on selected presentations will be provided as data are released at the meeting.

Thursday June 5:

Abstract # 172 -- A Comparison of Adenovirus Infection and Plasmid Electroporation-Mediated Transgene Delivery in Rat Skeletal Muscle. Venstrom et al., 4.00-7.00 PM.

Abstract # 173 -- Non-viral Delivery of Engineered Zinc Finger Transcriptional Activators to Skeletal Muscle. Spratt, et al., 4.00-7.00 PM.

Friday, June 6:

Abstract # 516 -- Adenovirus Production Using a Regulatable System. Liang et al., 4.00-7.00 PM.

Abstract # 603 -- Induction of Angiogenesis in Rat Skeletal Muscle Using a Designed Zinc Finger Protein Transcriptional Activator Targeted to Vascular Endothelial Growth Factor A (VEGF A). B. Johnstone et al., 4.00-7.00 PM.

Abstract # 776 -- ZFP Transcription Therapy -- Single Gene Specificity Genome Wide. Gregory et al., 4.00-7.00 PM.

Abstract # 780 -- Repression of Endogenous VEGF-A Gene with Engineered Zinc Finger Protein Transcription Factors. Zhang et al., 4.00-7.00 PM.

Abstract # 786 -- Transcriptional Activation of the Endogenous VEGF Gene by Small Molecule Regulated Engineered Transcription Factors. Dent et al., 4.00-7.00 PM.

Saturday, June 7:

Abstract # 855 -- A Genetically Engineered Plasmid Encoding a Zinc Finger VEGF-Activating Transcription Factor Induces Angiogenesis in the Rabbits with Hind-Limb Ischemia. B. Annex et al., 9.00 AM-12.00 PM.

Abstract # 1154 -- Targeting in vivo Gene Correction Using Designed DNA-Binding Proteins. Urnov, Miller and Pabo., 4.00-7.00 PM.

Sunday, June 8:

Abstract # 1191 -- Peptide-Mediated Delivery of Artificial Transcription Factors to Upregulate Specific Endogenous Gene Expression: A Novel Approach to Gene Therapy. Giordano et al., 10:00 AM.

Abstract # 1192 -- Robust Activation of Vascular Endothelial Growth Factor-A Using Designed Zinc Finger Protein Transcription Factors. Rebar et al., 10:15 AM.

About Sangamo

Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company's most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Other therapeutics development programs are focused on cancer, neuropathic pain, ophthalmic and infectious diseases. Sangamo's proprietary technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery and plant agriculture. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF Therapeutic programs. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., +1-510-970-6000, ext. 271, or ewolffe@sangamo.com Web site: http://www.asgt.org Web site: http://www.sangamo.com